Cidofovir for cytomegalovirus-preemptive therapy in stem cell transplant recipients [1]

Blood

Volumn 98, Issue 5, 2001, Pages 1626-

  Kiehl, Michael G ^a   Basara, Nadesta ^a  

^a BMT Unit   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CIDOFOVIR; FOSCARNET; GANCICLOVIR;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; CHEMOPROPHYLAXIS; CHRONIC MYELOID LEUKEMIA; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LETTER; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; SIDE EFFECT; VIRUS TRANSMISSION;

EID: 0035469828     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.5.1626     Document Type: Letter

References (3)

1. Ljungman P, Delitiers GL, Platzbecker U, et al. Cidofovir for cytomegalovirus infection and disease in allogeneic stem cell transplant recipients. Blood. 2001;97:388-392.
2. Ljungman P, Griffiths P. Definitions of cytomegalovirus infection and disease. In: Michelson S, Plotkin S, eds. Multidisciplinary approach to understanding cytomegalovirus disease. New York, NY: Elsevier Science; 1993:98-136.
3. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645-649.